BEAM Stock Analysis: Beam Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.118m USD | 12M Return: 80.4% | US07373V1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 44.7M
Qual. Beats: -1
Rev. Trend: -34.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Beam Therapeutics Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that develops precision genetic medicines using base editing technology to treat serious diseases. Its pipeline includes therapies for sickle cell disease, alpha-1 antitrypsin deficiency, phenylketonuria, and glycogen storage disease type 1a, alongside the ESCAPE platform for antibody-based conditioning with gene-edited hematopoietic stem cells. The company maintains research collaborations with Pfizer, Verve Therapeutics, and Orbital Therapeutics across liver, muscle, cardiovascular, and central nervous system targets. Founded in 2017, Beam went public on NASDAQ in February 2020 and operates within the high-risk, research-intensive biotechnology sector, where companies typically rely on partnerships, grant funding, and capital markets to finance lengthy drug development cycles before achieving commercial revenue.
- Ristoglogene SCD Phase 1/2 data readout approaches
- Cash burn and financing risk pressure pipeline runway
- Pfizer in vivo base editing collaboration advances toward milestones
| Net Income: -85.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA 12.74 > 1.0 |
| NWC/Revenue: 703.5% < 20% (prev 1.66k%; Δ -957.9% < -1%) |
| CFO/TA -0.26 > 3% & CFO -359.4m > Net Income -85.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.3m) vs 12m ago 2.29% < -2% |
| Gross Margin: 85.71% > 18% (prev -557.5%; Δ 643.2% > 0.5%) |
| Asset Turnover: 11.24% > 50% (prev 4.33%; Δ 6.90% > 0%) |
| Interest Coverage Ratio: -2.12 > 6 (EBIT TTM -82.5m / Interest Expense TTM 38.9m) |
| A: 0.79 (Total Current Assets 1.18b - Total Current Liabilities 80.9m) / Total Assets 1.39b |
| B: -1.34 (Retained Earnings -1.86b / Total Assets 1.39b) |
| C: -0.06 (EBIT TTM -82.5m / Avg Total Assets 1.39b) |
| D: 3.34 (Book Value of Equity 1.07b / Total Liabilities 319.2m) |
| Altman-Z'' = 3.94 = AA |
As of September 01, 2026, the stock is trading at USD 29.43 with a total of 1,307,692 shares traded. Over the past week, the price has changed by +3.88%, over one month by +15.32%, over three months by -5.49% and over the past year by +80.44%.
Current recommended Stop Loss: 26.50 (which is 10% or 1.8 ATR below the current price).
Beam Therapeutics has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy BEAM.
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.2 | 77.2% |
P/S = 19.9843
P/B = 3.0025
Revenue TTM = 156.0m USD
EBIT TTM = -82.5m USD
EBITDA TTM = -60.3m USD
Long Term Debt = 100.3m USD (from longTermDebt, last quarter)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 394.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 147.1m
Net Debt = -758.5m USD (calculated: Debt 394.5m - CCE 1.15b)
Enterprise Value = 2.36b USD (3.12b + Debt 394.5m - CCE 1.15b)
Interest Coverage Ratio = -2.12 (Ebit TTM -82.5m / Interest Expense TTM 38.9m)
EV/FCF = -26.42x (Enterprise Value 2.36b / FCF TTM -89.3m)
FCF Yield = -3.78% (FCF TTM -89.3m / Enterprise Value 2.36b)
FCF Margin = -57.23% (FCF TTM -89.3m / Revenue TTM 156.0m)
Net Margin = -54.75% (Net Income TTM -85.4m / Revenue TTM 156.0m)
Gross Margin = 85.71% ((Revenue TTM 156.0m - Cost of Revenue TTM 22.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev 65.16%)
Tobins Q-Ratio = 1.70 (Enterprise Value 2.36b / Total Assets 1.39b)
Interest Expense / Debt = 9.86% (Interest Expense 38.9m / Debt 394.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -65.2m (EBIT -82.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.54 (Total Current Assets 1.18b / Total Current Liabilities 94.0m)
Debt / Equity = 0.37 (Debt 394.5m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 12.58 (negative EBITDA) (Net Debt -758.5m / EBITDA -60.3m)
Debt / FCF = 8.49 (negative FCF - burning cash) (Net Debt -758.5m / FCF TTM -89.3m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.15% (Net Income -85.4m / Total Assets 1.39b)
RoE = -7.70% (Net Income TTM -85.4m / Total Stockholder Equity 1.11b)
RoCE = -6.83% (EBIT -82.5m / Capital Employed (Equity 1.11b + L.T.Debt 100.3m))
RoIC = -4.97% (negative operating profit) (NOPAT -65.2m / Invested Capital 1.31b)
WACC = 13.07% (E(3.12b)/V(3.51b) * Re(13.74%) + D(394.5m)/V(3.51b) * Rd(9.86%) * (1-Tc(0.21)))
Discount Rate = 13.74% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.99 | Cagr: 11.48%
[DCF] Fair Price = unknown (Cash Flow -89.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.86 | # QB: -1
Revenue Correlation: -34.73 | Revenue CAGR: -25.98% | SUE: -0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.17 | Chg30d=+0.42% | Revisions=-8% | Analysts=13
EPS current Year (2026-12-31): EPS=-4.45 | Chg30d=-0.43% | Revisions=-8% | GrowthEPS=-449.8% | GrowthRev=-65.2%
EPS next Year (2027-12-31): EPS=-4.74 | Chg30d=-0.19% | Revisions=+18% | GrowthEPS=-6.5% | GrowthRev=+29.2%
[Analyst] Revisions Ratio: +0% (up=13, down=13)